Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Shimasaki Yukio; Sakaki Masashi; Itou Minoru; Kobayashi Tokurou; Aso Masako; Kagawa Tomoya; Saiki Takuya; Matsuno Kumi; Sano Yuhei; Shimizu Kohei; Kuroda Shingo; Koumura Emiko

首页> 外文期刊>Clinical drug investigation >Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

【24h】

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

机译：在肾癌或肝损伤的受试者中单剂量伊马里克后的药代动力学和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Objective Imarikiren hydrochloride (TAK-272; SCO-272) is a novel direct renin inhibitor. The objective of this study was to determine the effects of renal impairment (RI) or hepatic impairment (HI) on the pharmacokinetics and safety of imarikiren.

机译：背景和物镜伊马基酮盐酸盐（TAK-272; SCO-272）是一种新型肾素抑制剂。本研究的目的是确定肾脏损伤（RI）或肝损伤（HI）对Imarikiren的药代动力学和安全的影响。

著录项

来源
《Clinical drug investigation》 |2018年第11期|共11页
作者
Shimasaki Yukio; Sakaki Masashi; Itou Minoru; Kobayashi Tokurou; Aso Masako; Kagawa Tomoya; Saiki Takuya; Matsuno Kumi; Sano Yuhei; Shimizu Kohei; Kuroda Shingo; Koumura Emiko;
展开▼
作者单位

Takeda Pharmaceut Co Ltd Tokyo Japan;

Showa Univ Sch Med Dept Med Div Gastroenterol Tokyo Japan;

Kurume Univ Sch Med Dept Med Div Gastroenterol Fukuoka Fukuoka Japan;

Moriya Keiyu Hosp Ibaraki Japan;

Kitasato Univ Hosp Sagamihara Kanagawa Japan;

SCOHIA PHARMA Inc Fujisawa Kanagawa Japan;

SCOHIA PHARMA Inc Fujisawa Kanagawa Japan;

Takeda Pharmaceut Co Ltd Osaka Japan;

Takeda Pharmaceut Co Ltd Osaka Japan;

Takeda Pharmaceut Co Ltd Osaka Japan;

Takeda Pharmaceut Co Ltd Osaka Japan;

Takeda Pharmaceut Co Ltd Osaka Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment [J] . Shimasaki Yukio, Sakaki Masashi, Itou Minoru, Clinical drug investigation . 2018,第11期

机译：在肾癌或肝损伤的受试者中单剂量伊马里克后的药代动力学和安全性
2. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects [J] . Dymond Angela W., Martin Paul, So Karen, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2017,第5期

机译：与健康受试者相比，单次口服剂量的Mek1 / 2抑制剂Selumetinib的单次口服剂量的Mek1 / 2抑制剂Selumetinib或不同程度的肝障碍程度
3. An Open-Label Study to Estimate the Effect of Steady-State Erythromycin on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban in Subjects with Renal Impairment and Normal Renal Function [J] . Moore Kenneth T., Vaidyanathan Seema, Natarajan Jaya, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2014,第12期

机译：一项开放标签研究，以评估稳态红霉素对肾功能不全和肾功能正常的受试者的单药剂量利伐沙班的药代动力学，药效学和安全性的影响
4. MATURE MYSTERIES: "OLD AGE AIN'T NO PLACE FOR SISSIES" MANAGING OSTEOARTHRITIS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT [C] . Gregory F. Grauer Annual Meeting of the American Animal Hospital Association . 2008

机译：成熟的谜团：“旧时代不是啜饮的地方”管理肾病或肝病患者骨关节炎
5. Design evaluation for pharmacokinetic studies in patients with renal impairment [D] . Liu, Jin 2007

机译：肾功能不全患者药代动力学研究的设计评估
6. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects [O] . Angela W. Dymond, Paul Martin, Karen So, -1

机译：与健康受试者相比MEK1 / 2抑制剂Selumetinib单次口服剂量在患有终末期肾脏疾病或肝功能不全程度的受试者中的药代动力学
7. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment [O] . Yukio Shimasaki, Masashi Sakaki, Minoru Itou, 2018

机译：在肾癌或肝损伤的受试者中单剂量伊马里克后的药代动力学和安全性
8. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function211 Study Design, Data Analysis, and Impact on Dosing and Labeling [R] . 1998

机译：工业指南。肾功能受损患者的药代动力学211研究设计，数据分析以及对剂量和标记的影响

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

摘要

著录项

相似文献

相关主题

期刊订阅